Abstract |
The purpose of this study was to evaluate the efficacy, safety, and tolerance of pindolol as initial therapy for vasovagal syncope. Head-up tilt table testing (HUT) was performed on 192 patients for syncope or near- syncope of unknown cause. Forty-four (23%) patients had a positive HUT for vasovagal syncope, and 28 (64%) received oral pindolol as initial therapy. Three patients were lost to follow-up; of the remaining 25 patients (mean age 60 +/- 22 years), 15 were women, 14 had syncope, and 11 had near- syncope. At 14 +/- 6 months' follow-up, 16 (64%) patients were without recurrence or side effects from pindolol. Of the 9 patients who stopped taking pindolol, 3 were switched to another regimen for recurrent symptoms, 2 stopped because of side effects, and 4 did not comply with the regimen. In conclusion, pindolol appears to be safe and effective as initial treatment for vasovagal syncope.
|
Authors | M B Cohen, J S Snow, V Grasso, L Lehnert, B G Goldner, R L Jadonath, T J Cohen |
Journal | American heart journal
(Am Heart J)
Vol. 130
Issue 4
Pg. 786-90
(Oct 1995)
ISSN: 0002-8703 [Print] United States |
PMID | 7572587
(Publication Type: Journal Article)
|
Chemical References |
- Adrenergic beta-Antagonists
- Sympathomimetics
- Pindolol
|
Topics |
- Adolescent
- Adrenergic beta-Antagonists
(therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Evaluation Studies as Topic
- Female
- Humans
- Male
- Middle Aged
- Pindolol
(therapeutic use)
- Sympathomimetics
(therapeutic use)
- Syncope
(drug therapy)
- Tilt-Table Test
- Treatment Outcome
|